



Around the world of U.S. healthcare in 360 words or less

Center for Healthcare Regulatory Insight



September 1, 2023 | Issue 286

Editor's note

This note is produced every Friday by the [KPMG Center for Healthcare Regulatory Insight](#) and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to [subscribe to our mailing list here](#).

We welcome your feedback. Let us know if KPMG can help. Please [reply here to me](#), **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

[> Subscribe here](#)



Healthcare regulatory news

CMS [announced](#) the [first 10 drugs selected](#) for the Medicare Drug Price Negotiation Program.

CMS [finalized plans requiring states to annually report](#) on three Medicaid/CHIP quality measure sets.

OMB [completed review of a CMS proposed rule](#) on long-term care facility staffing minimums and began review of two [proposed rules](#) on the *No Surprises Act* independent dispute resolution process.

HHS sent [letters ordering all 50 states](#), DC, and territories to [review Medicaid redetermination processes](#) to ensure beneficiaries, particularly children, are not incorrectly disenrolled, and to immediately take corrective action.

OIG [released a strategic plan](#) for Medicare and Medicaid managed care oversight.

FDA released guidance (1) [providing drug supply chain stakeholders](#) an extra year (November 2024) to comply with *Drug Supply Chain Security Act* requirements; and, (2) detailing [use of real-world evidence to support approval](#) of new indications for drugs/biologics.

→



Healthcare law and policy news

The [White House announced \\$450M](#) to support opioid epidemic efforts.

AstraZeneca [sued](#) to [stop implementation](#) of the Medicare Drug Price Negotiation Program.

A [federal district court ruled](#) *No Surprises Act* regulations, including on [“qualifying payment amount” calculations, were unlawful](#) and must be set aside due to conflicts with the law.

Novo Nordisk [acquired Embark Biotech](#) (\$512M)... FTC [suspended its challenge of Amgen’s acquisition](#) of Horizon Therapeutics, creating opportunity for a possible settlement to close the deal... Rite Aid is [preparing to file for bankruptcy](#) to address opioid-related federal and state lawsuits, while [Mallinckrodt went bankrupt for a second time](#) to reduce costs of its opioid settlement... An over-the-counter version of Narcan, [available at retailers this month, will cost \\$45](#)... GoodRx [integrated real-time benefit check features](#) into its provider-facing cost comparison tool.

A [JAMA study found](#) utilization and spending rates for mental health services increased 38.8% and 53.7%, respectively, between 2019-2022... A [JAMA meta-analysis concluded](#) current evidence does not support the claim that six commonly used cancer screening tests save lives by extending lifetime, except possibly for colorectal cancer screening with sigmoidoscopy... A [study found ChatGPT was 72% accurate](#) overall in decision-making based on clinical vignettes; a correct final diagnosis was reached 77% of the time.

Kaufman Hall [reported median year-to-date hospital operating margins](#) were 1.3% in July, down from 1.4% in June.

→



Questions or comments, please send to us-hclspractice@kpmg.com.

kpmg.com/socialmedia



[Privacy](#) | [Legal](#)

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please [click here](#). If you wish to unsubscribe from all KPMG communications, please [click here](#).

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1E

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.